Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology a...

ver descrição completa

Detalhes bibliográficos
Autores: Bellet, Meritxell, Ahmad, Faten, Villanueva, Rafael, Valdivia, Carolina, Palomino-Doza, Julian, Ruiz, Ada, Gonzalez, Xavier, Adrover, Encarna, Azaro, Analia, Valls-Margarit, Maria, Parra, Josep Lluis, Aguilar, Juan, Vidal, Maria, Martin, Anastasi, Gavila, Joaquin, Escriva-de-Romani, Santiago, Perello Martorell, Antonia, Hernando, Cristina, Lahuerta, Ainhara, Zamora, Pilar, Reyes, Victoria, Alcalde, Maria, Masanas, Helena, Celiz, Pamela, Ruiz, Isabel, Gil, Miguel, Segui, Miguel Angel, de la Pena, Lorena
Formato: artículo
Fecha de publicación:2019
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/22805
Acesso em linha:https://hdl.handle.net/20.500.12105/22805
Access Level:acceso abierto
Palavra-chave:CDK inhibitors
Palbociclib
Ribociclib
Breast cancer
id ES_50436597842ec0b8eeb42d8a65dfcdb9
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/22805
network_acronym_str ES
network_name_str España
repository_id_str
spelling Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medicationBellet, MeritxellAhmad, FatenVillanueva, RafaelValdivia, CarolinaPalomino-Doza, JulianRuiz, AdaGonzalez, XavierAdrover, EncarnaAzaro, AnaliaValls-Margarit, MariaParra, Josep LluisAguilar, JuanVidal, MariaMartin, AnastasiGavila, JoaquinEscriva-de-Romani, SantiagoPerello Martorell, AntoniaHernando, CristinaLahuerta, AinharaZamora, PilarReyes, VictoriaAlcalde, MariaMasanas, HelenaCeliz, PamelaRuiz, IsabelGil, MiguelSegui, Miguel Angelde la Pena, LorenaCDK inhibitorsPalbociclibRibociclibBreast cancerDrug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.SAGE Publishing20242024-09-1020192019-05-0120192019-05-01review articlehttp://purl.org/coar/resource_type/c_dcae04bcinfo:eu-repo/semantics/articlehttps://hdl.handle.net/20.500.12105/22805reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/228052026-06-12T12:43:37Z
dc.title.none.fl_str_mv Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
spellingShingle Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Bellet, Meritxell
CDK inhibitors
Palbociclib
Ribociclib
Breast cancer
title_short Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_full Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_fullStr Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_full_unstemmed Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_sort Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
dc.creator.none.fl_str_mv Bellet, Meritxell
Ahmad, Faten
Villanueva, Rafael
Valdivia, Carolina
Palomino-Doza, Julian
Ruiz, Ada
Gonzalez, Xavier
Adrover, Encarna
Azaro, Analia
Valls-Margarit, Maria
Parra, Josep Lluis
Aguilar, Juan
Vidal, Maria
Martin, Anastasi
Gavila, Joaquin
Escriva-de-Romani, Santiago
Perello Martorell, Antonia
Hernando, Cristina
Lahuerta, Ainhara
Zamora, Pilar
Reyes, Victoria
Alcalde, Maria
Masanas, Helena
Celiz, Pamela
Ruiz, Isabel
Gil, Miguel
Segui, Miguel Angel
de la Pena, Lorena
author Bellet, Meritxell
author_facet Bellet, Meritxell
Ahmad, Faten
Villanueva, Rafael
Valdivia, Carolina
Palomino-Doza, Julian
Ruiz, Ada
Gonzalez, Xavier
Adrover, Encarna
Azaro, Analia
Valls-Margarit, Maria
Parra, Josep Lluis
Aguilar, Juan
Vidal, Maria
Martin, Anastasi
Gavila, Joaquin
Escriva-de-Romani, Santiago
Perello Martorell, Antonia
Hernando, Cristina
Lahuerta, Ainhara
Zamora, Pilar
Reyes, Victoria
Alcalde, Maria
Masanas, Helena
Celiz, Pamela
Ruiz, Isabel
Gil, Miguel
Segui, Miguel Angel
de la Pena, Lorena
author_role author
author2 Ahmad, Faten
Villanueva, Rafael
Valdivia, Carolina
Palomino-Doza, Julian
Ruiz, Ada
Gonzalez, Xavier
Adrover, Encarna
Azaro, Analia
Valls-Margarit, Maria
Parra, Josep Lluis
Aguilar, Juan
Vidal, Maria
Martin, Anastasi
Gavila, Joaquin
Escriva-de-Romani, Santiago
Perello Martorell, Antonia
Hernando, Cristina
Lahuerta, Ainhara
Zamora, Pilar
Reyes, Victoria
Alcalde, Maria
Masanas, Helena
Celiz, Pamela
Ruiz, Isabel
Gil, Miguel
Segui, Miguel Angel
de la Pena, Lorena
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv CDK inhibitors
Palbociclib
Ribociclib
Breast cancer
topic CDK inhibitors
Palbociclib
Ribociclib
Breast cancer
description Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-05-01
2019
2019-05-01
2024
2024-09-10
dc.type.none.fl_str_mv review article
http://purl.org/coar/resource_type/c_dcae04bc
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/22805
url https://hdl.handle.net/20.500.12105/22805
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE Publishing
publisher.none.fl_str_mv SAGE Publishing
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407871012175872
score 15.81155

Registos relacionados